Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Known as: HBV Nucleoside Analog Reverse Transcriptase Inhibitor (HBV-NRTI), HBV NRTI, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor 
 
National Institutes of Health

Related topics

Related topics

3 relations
Hepatitis BNucleoside AnalogsNucleoside Reverse Transcriptase Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Correction for Sohl et al., Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ
BIOCHEMISTRY Correction for “Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA… Expand
  • figure 5
2016
2016
Neuer NRTI für die HIV-Therapie
Auf dem Kongress der Gesellscha für Phytotherapie 2016 wurde eine aktuelle nicht-interventionelle Studie zur Behandlung von… Expand
2015
2015
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ
Significance Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the cornerstones of treatment for fighting HIV… Expand
  • figure 5
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
NRTI Backbone in HIV Treatment
Nucleoside reverse transcriptase inhibitors (NRTIs) remain a critical component of therapy for HIV-infected patients. The drugs… Expand
  • table I
  • table II
2012
2012
Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment‐naïve HIV‐infected individuals
In two 48‐week studies in naïve subjects, dolutegravir with NRTI of choice has shown non‐inferiority to raltegravir and, with ABC… Expand
2008
2008
Short communication: the number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility…
While it is known that selection for specific HIV-1 drug resistance-associated mutations (DRM) occurs following ART failure, the… Expand
  • table 1
  • figure 1
2008
2008
Effects of NRTI Backbone on Efficacy of First-line Boosted Pi Based Haart - Meta-analysis of 12 Clinical Trials in 4896 Patients
 
2007
2007
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
BACKGROUND Intracellular nucleoside reverse transcriptase inhibitor triphosphate (NRTI-TP) concentrations are crucial in… Expand
  • table 1
  • table 2
  • figure 1
2007
2007
Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone
We evaluated the efficacy of tenofovir (TDF) – and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We… Expand
  • table 1
  • table 2
  • table 3
2003
2003
Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE